论文部分内容阅读
目的观察前列腺素E1脂微球载体制剂(Lipo PGE1)治疗肝硬化腹腔积液的疗效。方法将肝硬化腹腔积液病人84例随机分为两组,对照组42例、治疗组42例,对照组常规保肝利尿治疗,治疗组在对照组治疗方案的基础上加用凯时(Lipo PGE1)10μg/d(A组)或20μg/d(B组),疗程14天,观察临床体征变化如腹腔积液消退和两组的肝功改善情况,并记录副作用。结果治疗组有效率明显高于对照组(85.71%:59.52%,P=0.013),治疗前后丙氨酸转移酶(ALT)、总胆红素(TBIL)、肌酐(Cr)、尿素氮(BUN)等指标均在疗程结束时得到明显改善(P<0.05),其中TBIL、Cr水平的下降明显优于对照组(P=0.017,0.008)。治疗组A、B之间无显著性差异。结论前列腺素E1脂微球载体制剂有促进腹腔积液消退、改善肝功的作用,且无明显刺激性反应。
Objective To observe the efficacy of Lipo PGE1 in the treatment of liver cirrhosis and ascites. Methods Eighty-four patients with cirrhosis and ascites were randomly divided into two groups: control group (n = 42), treatment group (n = 42) and control group. The treatment group was treated with Lipo PGE1) 10μg / d (group A) or 20μg / d (group B) for 14 days. The changes of clinical signs such as the regression of ascites and improvement of liver function were observed and the side effects were recorded. Results The effective rate of treatment group was significantly higher than that of control group (85.71% vs 59.52%, P = 0.013). ALT, TBIL, BUN, BUN ) And other indicators were significantly improved at the end of treatment (P <0.05), of which TBIL, Cr levels were significantly better than the control group (P = 0.017,0.008). Treatment group A, B no significant difference between. Conclusion Prostaglandin E1 lipid microspheres carrier formulations can promote ascites effusion, improve liver function, and no significant irritant response.